Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Christina Swanson, PhD, Trevor Do, Samantha Merrigan, Shaparak Lonning, Kim Merriam, Joshua Prentiss, Janani Sridar, Claire L Sutherland, PhD, Benhuai Xie, PhD, Minh Pham, Daniel Li, PhD, Tina Albertson, MD, Howard M Stern, MDPhD, Sharon Moulis, PhD

Blood (2017) 130 (Supplement 1): 194.

https://doi.org/10.1182/blood.V130.Suppl_1.194.194

Published: 2017

Journal Articles

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Marisa Peluso, MS, Kerrie Faia, MS, David Winkler, PhD, Nidhi Patel, MS, Erin Brophy, BS, Kerry White, BA, Mark Douglas, MS, Howard M. Stern, MD PhD, Vito Palombella, PhD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD

Blood (2014) 124 (21): 328.

https://doi.org/10.1182/blood.V124.21.328.328

Published: 2014

Journal Articles

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Susan O'Brien, Manish Patel, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Pierluigi Porcu, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Howard M. Stern, MD PhD, Patrick Kelly, MD, Ian Flinn

Blood (2014) 124 (21): 3334.

https://doi.org/10.1182/blood.V124.21.3334.3334

Published: 2014

Journal Articles

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Steven M. Horwitz, MD, Yasuhiro Oki, John C. Byrd, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Min Ni, PhD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Susan O'Brien

Blood (2014) 124 (21): 3335.

https://doi.org/10.1182/blood.V124.21.3335.3335

Published: 2014

Journal Articles

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian Flinn, Yasuhiro Oki, MD, Manish Patel, Steven M. Horwitz, MD, Francine M. Foss, MD, Jennifer Sweeney, Kerstin Allen, MA, Mark Douglas, MS, Lori Steelman, Joi Dunbar, PharmD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Brad Kahl, MD

Blood (2014) 124 (21): 802.

https://doi.org/10.1182/blood.V124.21.802.802

Published: 2014

Journal Articles

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

Steven M. Horwitz, MD, Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Jennifer Sweeney, Howard M. Stern, MD PhD, Mark Douglas, MS, Kerstin Allen, MA, Patrick Kelly, MD, Francine M. Foss, MD

Blood (2014) 124 (21): 803.

https://doi.org/10.1182/blood.V124.21.803.803

Published: 2014

Journal Articles

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

Veronica Campbell, BS, Ryan Thompson, PhD, Vivian Villegas, MS, Jennifer Proctor, B.S., Karen McGovern, PhD, Jeffery L. Kutok, MD, PhD, Howard M. Stern, M.D., Ph.D.

Blood (2013) 122 (21): 1832.

https://doi.org/10.1182/blood.V122.21.1832.1832

Published: 2013

Journal Articles

Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Mark Douglas, M.S., Ken Allison, M.S., Synder Ted, B.A., Kerstin Allen, MA, Brad S. Kahl, MD, Steven M. Horwitz, MD, Ian W. Flinn, MD, PhD, Patrick Kelly, MD, Howard M. Stern, M.D., Ph.D

Blood (2013) 122 (21): 1633.

https://doi.org/10.1182/blood.V122.21.1633.1633

Published: 2013

Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 677.

https://doi.org/10.1182/blood.V122.21.677.677

Published: 2013

Journal Articles

Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation

David Traver, Alissa Winzeler, Howard M. Stern, Elizabeth A. Mayhall, David M. Langenau, Jeffrey L. Kutok, A. Thomas Look, Leonard I. Zon

Blood (2004) 104 (5): 1298–1305.

https://doi.org/10.1182/blood-2004-01-0100

Published: 2004

Includes: Multimedia, Supplemental data

NARROW

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only